The purpose of our study is to determine the outcome of patients with systemic nonHodgkin's Lymphoma presenting with neurologic localization at diagnosis, as well as the impact of consolidation in terms of high dose therapy followed by autologous stem cell transplantation.
Introduction
Central nervous system (CNS) and peripheral neurologic (PN) involvement at initial presentation of systemic diffuse large B-cell type lymphomas (DLBCL) represent less than 5 % of systemic non-Hodgkin's Lymphoma (sNHL) cases. [1] [2] [3] [4] Although the prognosis of patients with systemic B-cell non-Hodgkin's lymphoma (NHL) has improved over the last decades, these advances have not been noted across all types of NHL and varied according to the initial lymphoma sites especially CNS localization. Systemic NHL in addition to neurologic involvement remains therapeutically challenging and is associated with poor outcome. Recent retrospectives studies have highlighted the devastating prognosis of CNS involvement at relapse of sNHL with a median overall survival (OS) of 7 months to 1.6 y from the time of CNS relapse. 5, 6 Little is known on the prognosis of concurrent involvement of CNS or PN at initial diagnosis of sNHL; such patients are excluded from therapeutic trials. The aim of our study is to report on the therapeutic characteristics of these patients as well as on the role of high dose therapy and autologous stem cell transplantation in these settings.
Methods

Study design
Patients with histologically confirmed diagnosis of non-Hodgkin's Lymphoma (NHL) made between May 2002 and January 2012 with concomitant systemic and neurologic involvement were retrieved from the database of the participating centers, from The Lymphoma Study Association (LYSA) database and the French network for oculocerebral lymphoma (LOC).
In accordance with the declaration of Helsinki, approval of the University Hospital of Amiens Nord-Ouest II Ethics Committee was obtained.
Patient eligibility
Patients 18 years or older with a sNHL diagnosis with nervous system involvement were eligible for this study. Diagnosis of NHL was made according to international diagnostic criteria used at the time of diagnosis. Diagnosis of systemic lymphoma was done on lymph nodes or using tissue biopsies. Nervous system involvement was defined by brain parenchyma, intra-ocular, cranial nerve, or meningeal involvement, as well as paravertebral mass and CSF involvement with lymphoma cells. Diagnosis was based on positive cerebrospinal fluid (CSF) cytology or immunophenotyping or by biopsy-proven parenchymal brain localization. Patients with CNS localization based on a typical CT-scan and/or magnetic resonance imaging (MRI) and concurrent sNHL were included as well.
Treatment and Assessments
At baseline assessments of patients and disease included ECOG score, Ann Arbor stage, international prognostic index (IPI), lactate dehydrogenase (LDH) level, bone marrow histology, CSF cytological and/or flow cytometry analysis, CT-scan of the thorax, abdomen and pelvis. Cerebral and vertebral CT-scan and/or MRI were also recorded.
The type of chemotherapy administered, total dose of drugs per cycle and the use of high dose therapy as well as radiotherapy were retrieved from the original patient files.
Response assessment was performed by the on-site referent physician according to the International Working Group Criteria (IWC) for sNHL and the International Primary CNS Lymphoma Collaborative Group for CNS disease.
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Statistical Methods
Quantitative variables were expressed as mean ± standard deviation or as median [range] and qualitative variables as percentages. The Student or Wilcoxon test was used for comparison of quantitative variables between two groups. Chi-square or Fisher's test were used to compare categorical variables. Overall survival (OS) was defined as the time between diagnosis and the date of death or last follow-up. Univariate standard and time-varying (for Intensive therapy) Cox models were used to assess prognostic factors for overall survival and to compute hazard ratios (HRs) and their 95% confidence interval (95%CI).
Variables eligible for the multivariate time-varying Cox model were those variables having a p value < 0.10 in univariate analysis.
Survival distributions were estimated using the adjusted Kaplan-Meier method. P-values were two sided and values <0.05 were considered significant in multivariate analysis. SAS software version 9.2® (SAS Institute, Cary, NC) was used for all analysis.
Results
Patient characteristics (table 1)
Eighty-three patients were initially identified in our databases. Twenty three patients were excluded from the analysis on account of missing data or uncertain diagnosis (n=14), for Burkitt's lymphoma diagnosis (n=4) or unspecified small B-cell lymphoma (n=2) or follicular lymphoma (n=3). A total of 35 male and 25 female patients with a median age of 61 (23-85) years at lymphoma diagnosis were analyzed.
Histopathological subtypes were predominantly diffuse large B-cell (DLBCL) (n=54; 90%).
Other histology included mantle cell lymphoma (n=2), peripheral T-cell lymphoma (n=2) and anaplastic large cell lymphoma ALK+ (n=1) and unclassified high grade lymphoma (n=1).
Histological diagnosis was made on lymph nodes (n=42), CNS (n=1), paravertebral mass (n=12) and other extra nodal tissue (n=5) biopsies.
In DLBCL cases, the IPI was high in 72% of cases and LDH level was above normal value in 60% of cases. Extra nodal disease was present at 2 or more sites in 75% of patients and in 45% of patients, bone marrow involvement was detected.
CNS involvement such as parenchymal, intraventricular, meningeal or cranial nerve was documented in 48 patients. Seven patients had paravertebral involvement with an epidural mass, cord compression and CSF involvement by lymphoma cells and 5 patients had both CNS and paravertebral nervous system lesions. Forty three patients had data regardind CSF involvement. Thirteen patients had CSF involvement with lymphoma whereas 30 patients did not. No patients had a diagnosis of intra-ocular lymphoma.
As expected, patients above 60 years-old received less high dose therapy (p=0.006). (table 2) Anthracycline based chemotherapy was used in the majority of patients (n=53; 87%), either. alone (n= 8, 13%) or in combination with high dose methotrexate (HD-MTX) [R-CHOP-MTX (n=5). R-ACVBP (n=4); others (n=3)] or with HD-MTX plus high dose aracytine (HDaraC) (n=31). HD-MTX-based chemotherapy without anthracyclines was administered along with HD-araC in 4 patients. Two patients received MTX-based chemotherapy alone; 2 patients received palliative therapy. A total of 58 patients (97%) received a CNS-targeted chemotherapy.
Treatment
Induction chemotherapy
In the majority of patients, Rituximab immunotherapy was used in combination with chemotherapy (n=57; 95%). Three patients did not receive rituximab because of T-cell lymphoma. Intrathecal chemotherapy was added in 39 patients. Three patients received whole cranial irradiation and 1 patient received 30 grays radiotherapy at the vertebro-meningeal lesions.
High dose therapy and autologous stem cell transplant
IC + ASCT was performed in 19 (32%) patients (DLBCL=18, ALCL=1) as a consolidation therapy in first remission. Median patient age was 54 (23-67) years (only 1 patient > 65 years). Median time from diagnosis to ASCT was 6.1 (3.3 -14.5) months. Reasons for not receiving IC + ASCT were: progressive disease (n = 10), age > 65 years (n=15), premature toxic death (n=4) and physician decision (n=12).
In patients under 65 years old, reasons for not receiving IC +ASCT were progressive disease (n=5), toxic death (n=3) and physician decision (n =12).
High dose therapy consisted of BEAM (carmustine 300 mg/m²; day -6, etoposide 200 mg/m²; day -5 to -2, cytarabine 400 mg/m²; day -5 to -2, melphalan 140 mg/m² day -1) regimen (n=8), TBC (thiotepa 250 mg/m² day -9 to -7, busulfan 0.8 mg/kg every 6 hours day -6 to -4 (10 doses if ≤ 60 years and 8 doses if > 60 years) and cyclophosphamide 60 mg/kg day -3 to -2) regimen (n=8), total body irradiation, cyclophosphamide, etoposide (n =2) and cyclophosphamide, carmustine, etoposide and novantrone (n =1).
Among patients who received IC + ASCT, a higher proportion of patients were under 60 and presented more frequently an IPI < 3 at diagnosis as compared to patients who received conventional chemotherapy alone (table 1) . Other characteristics such as gender, ECOG score, LDH level, number of extranodal sites, pattern of nervous system involvement, and bone marrow infiltration were similar between the two patient groups.
Outcome
After induction chemotherapy, ORR was 76% with complete remission (CR) in 41 (68%) and partial remission in 5 (8%) patients. Ten patients had progressive disease during chemotherapy and 4 patients died during chemotherapy from treatment-related toxicity (severe sepsis=2; septic shock=3) and thus not evaluable for response. For patients who were in first CR, 19 received consolidative therapy with IC+ASCT and 22 patients did not.
For the whole group of patients, 3-yr overall survival (OS) and progression free survival (PFS) were 44 + 7% and 42 + 7 % respectively.
Eighteen patients relapsed after a median duration of response of 4.9 (0.7 -66) months. Five patients relapsed after ASCT and 13 patients after chemotherapy alone (from CR=12 or PR=1) with a median time duration of relapse of 9.8 (2 -66) and 4.8 (0.7 -34) months respectively.
After a median follow-up of 14.7 (0.1 -97) months from the diagnosis date, 32 patients died, from lymphoma (n=25) and sepsis (n=7). Twenty eight patients remained alive in CR (n=26) or PR (n=2).
Prognostic factors
For the whole group of patients:
In univariate analysis, 3-year OS was positively influenced by IC + ASCT (75% vs 29%; p=0.002). IC +ASCT had also a positive impact on 3-year PFS (75% vs 26%; p=0.001) (supplemental table 1; figure 2).
In multivariate analysis, 3-year OS and PFS were positively and significantly impacted by For patients under 65 years of age Thirty-nine patients were in first CR after induction chemotherapy. Nineteen received IC+ASCT and 20 patients did not. We compared the outcomes of the two groups.
In univariate analysis, 3-year OS and PFS were positively influenced by IC+ASCT 73% vs 28 %, p=0.0008; and 21 % vs 73 %, p = 0.003 respectively (table 3) . Eight patients received TBC as conditioning regimen and 8 others received BEAM regimen.
There was no difference between the 2 regimens regarding relapse rate and death.
Discussion
The worse prognosis of secondary CNS lymphoma defined by CNS involvement at any time during the course of sNHL, has been widely recognized when patients are treated with conventional chemotherapies. The rarity of this form of lymphoma, excluded from therapeutic trials, explains the lack of clear therapeutic guidelines for these patients.
We have reported a homogeneous series of adult patients with NHL presenting at diagnosis with concomitant systemic and neurologic involvement. Our population exhibits a high percentage of patients with elevated IPI and LDH level, and involvement of more than 2 extranodal sites, which are recognized as risk factors for CNS involvement by the lymphoma.
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The benefit of a consolidative strategy using IC + ASCT in the case of CNS relapse in sNHL has been previously suggested by retrospective studies from the European Group for Blood and Marrow Transplant (EBMT), the International Primary CNS Lymphoma Collaborative Group (IPCG), as well as retrospective, single center studies. This study provided sNHL data mainly at relapse. 5, 6, [11] [12] [13] [14] The benefit of such a strategy has not yet been shown in the specific setting of concomitant neurological and systemic NHL at diagnosis. Most of the published series included patients with CNS disease at diagnosis or at relapse. Due to the retrospective nature of the study, the small sample size and the absence of data on the choice of the treatment strategy, selection bias may have influenced patients' outcome. In this study which included exclusively patients who presented with systemic and neurologic lymphoma, the use of IC+ASCT in patients in CR confers a survival advantage compared to conventional chemotherapies without consolidation treatment.
In a study from the CIBMTR, Maziarz et al. reported on 151 adult patients with sNHL and CNS involvement at any time prior to ASCT. The authors confirm an excellent long-term outcome of patients who were transplanted in CNS remission at the time of transplant. with secondary CNS lymphoma, including 9 patients with CNS involvement at time or within 6 months of diagnosis of the sNHL. Excellent outcomes were reported; with a short median follow-up of 379 days, 1-year OS and PFS were 88% 80% PFS respectively.
The importance of obtaining complete remission especially of CNS lesions, before ASCT, has been recurrently showed. The use of HD-MTX before IC + ASCT was associated with a better PFS in one preliminary study, 16 whereas prior CNS radiotherapy has not be associated with a better survival after ASCT. relapse of a sNHL and treated with R-DHAP MTX followed by IC consisting of busulfan and cyclophosphamide. Results were disappointing with a median PFS of only 6 months.
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In our series, 8 patients received thiotepa, busulfan and cyclophosphamide (TBC) regimen and 8 others received BEAM regimen. There was no difference between the 2 regimens regarding relapse rate and mortality. However, the small number of patients precludes any firm conclusion.
Thus, we could consider, based on these results, despite the fact that only prospective randomized trials could answer this question, the combination of rituximab plus CHOP or CHOP-like chemotherapy in combination with HD-MTX +/-HD Ara-C, as the preferable first line treatment for patients with systemic and CNS NHL, followed in cases of complete remission, by an IC+ HCT. Although thiotepa-based conditionning has been more widely used in this patient setting, further study needs to be conducted on the best combination for the high dose therapy.
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